This trial determines the efficacy of the probiotic Bifidobacterium longum CECT 7347 (ES1) and postbiotic
heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in improving symptom severity in adults
with diarrhea-predominant irritable bowel syndrome (IBS-D). Two capsules of either
ES1, HT-ES1 or placebo were administered orally, once daily, for 84 days (12 weeks). The primary
outcome was change in total IBS-Symptom Severity Scale (IBS-SSS) score from baseline, compared to
placebo. Secondary outcome measures were stool consistency, quality of life, abdominal pain
severity and anxiety scores.

This is a prospective, randomized, double-blind, placebo-controlled, multi-center, and parallel-arm study, including two doses of the probiotic product and one placebo arm. The study investigated the clinical efficacy of Lactiplantibacillus plantarum Lpla33 in adults with IBS-D. A total of 333 screened participants were assessed for eligibility and 314 participants were randomized in the study. Three hundred and seven adults, 18-70 years of age, both male and female with IBS-D were allocated the (1:1:1) procedure.

Often called “The 5th largest probiotic study in digestive health”, this was a 319 subject trial conducted by Vedic for a US-based probiotic company across 12 sites in India. We studied the effect of 2 probiotic strains and placebo on adult men and women showing symptoms of IBS (Irritable Bowel Syndrome). Our strong network of gastroenterologists (investigators) helped recruit participants for this study over a span of 11 months. This clinical trial implemented reputed tools such as Bristol Stool Scale, IBS-SSS, Rome-IV criteria and APS-NRS. Contact us for the full paper.